PG
ALXN

Pendal Group’s Alexion Pharmaceuticals ALXN Stock Holding History

Pendal Group’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-30,609
Closed -$5.62M – 672
2021
Q2 		$5.62M Buy
30,609
+26,100
+579% +$4.48M 0.05% 134
2021
Q1 		$689K Buy
4,509
+1,267
+39% +$196K 0.01% 365
2020
Q4 		$506K Sell
3,242
-42,911
-93% -$5.51M 0.01% 373
2020
Q3 		$5.28M Sell
46,153
-3,093
-6% -$334K 0.06% 97
2020
Q2 		$5.53M Sell
49,246
-3,283
-6% -$349K 0.08% 100
2020
Q1 		$4.72M Sell
52,529
-13,218
-20% -$1.3M 0.08% 92
2019
Q4 		$7.11M Buy
65,747
+64,212
+4,183% +$6.87M 0.09% 102
2019
Q3 		$150K Buy
+1,535
New +$173K ﹤0.01% 423
2018
Q1 		– Sell
-23,636
Closed -$2.83M – 511
2017
Q4 		$2.83M Buy
23,636
+22,461
+1,912% +$2.74M 0.04% 197
2017
Q3 		$165K Buy
+1,175
New +$160K ﹤0.01% 432

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Pendal Group's ALXN Position: Q3 2021 in Review

Pendal Group sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 30,609 shares — an estimated $5.62M sold.

Pendal Group first reported a position in ALXN in Q3 2017 and held it in 10 quarters. The position peaked at $7.11M in Q4 2019. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Pendal Group reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Pendal Group sold 30,609 Alexion Pharmaceuticals shares in Q3 2021, an estimated $5.62M.
  • Pendal Group first reported a position in Alexion Pharmaceuticals in Q3 2017 and held it in 10 quarters.
  • Pendal Group's Alexion Pharmaceuticals position peaked at $7.11M in Q4 2019.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Pendal Group's 13F filing for Q3 2021, filed 5 Nov 2021.